No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Recursion Pharmaceuticals (RXRX) and AN2 Therapeutics, Inc. (ANTX)
Insider Spends US$213k Buying More Shares In AN2 Therapeutics
Kevin Krause Named President and CEO of ArrePath
JMP Securities Maintains AN2 Therapeutics(ANTX.US) With Buy Rating, Maintains Target Price $5
TD Cowen Initiates AN2 Therapeutics(ANTX.US) With Hold Rating
Positive Outlook for AN2 Therapeutics: Buy Rating Justified by Strategic Pipeline Advancements and Strong Financial Health
Unlock the Full List